Erythrocyte membrane fatty acids in patients with multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 6, 2009, Pages 759-762

  Hon, G M ^a   Hassan, M S ^a   van Rensburg, S J ^b   Abel, S ^c   Marais, D W ^d   van Jaarsveld, P ^d   Smuts, C M ^d,e   Henning, F ^f   Erasmus, R T ^g   Matsha, Tandi ^a  

^a CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c NIRU   (South Africa)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e NORTH WEST UNIVERSITY   (South Africa)

^f STELLENBOSCH UNIVERSITY   (South Africa)

^g STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Multiple sclerosis; Outcome measurement; Relapsing remitting

Indexed keywords

FATTY ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLCHOLINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ERYTHROCYTE MEMBRANE; EXPANDED DISABILITY STATUS SCALE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; INDIVIDUALITY; LIPID COMPOSITION; MULTIPLE SCLEROSIS; PROTEIN DEPLETION; SCORING SYSTEM;

CHROMATOGRAPHY, GAS; DISABILITY EVALUATION; ERYTHROCYTE MEMBRANE; FATTY ACIDS; FEMALE; HUMANS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHOSPHATIDYLCHOLINES; SEVERITY OF ILLNESS INDEX;

EID: 66149174927     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509103321     Document Type: Article

References (13)

1. Koch, M, Ramsaransing, GSM, Fokkema, MR, Heersema, DJ, De Keyser, J. Erythrocyte membrane fatty acids in benign and progressive forms of multiple sclerosis. J Neurol Sci 2006; 244: 123-126.
2. Navarro, X, Segura, R. Red blood cell fatty acids in multiple sclerosis. Acta Neurol Scand 1989; 79: 32-37.
3. Harbige, LS, Sharief, MK. Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. Br J Nutr 2007; 98: S46-S53.
4. Kurtzke, JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
5. Folch, J, Lees, M, Sloane-Stanley, GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
6. Van Jaarsveld, PJ, Smuts, CM, Tichelaar, HY, Kruger, M, Benadé, AJS. Effect of palm oil on plasma lipoprotein concentrations and plasma low-density lipoprotein composition in non-human primates. Int J Food Sci Nutr 2000; 51: S21-S30.
7. Williams, EE. Membrane lipids: What membrane physical properties are conserved during physiochemicallyinduced membrane restructuring? Am Zool 1998; 38: 280-290.
8. Homa, ST, Belin, J, Smith, AD, Monro, JA, Zilkha, KJ. Levels of linoleate and arachidonate in red blood cells of healthy individuals and patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1980; 43: 106-110.
9. Baker, RWR, Thompson, RHS, Zilkha, KJ. Serum fatty acids in multiple sclerosis. J Neurol Neurosurg Psychiat 1964; 27: 408-414.
10. Holman, RT, Johnson, SB, Kokmen, E. Deficiencies of polyunsaturated fatty acids and replacement by nonessential fatty acids in plasma lipids in multiple sclerosis. Proc Natl Acad Sci USA 1989; 86: 4720-4724.
11. Horrobin, DF. The phospholipid concept of psychiatric disorders and its relationship to the neurodevelopmental concept of schizophrenia. In: Peet, M, Glen, I, Horrobin, DF, (eds), Phospholipid spectrum disorder in psychiatry, ch. 1. Lancashire, UK: Marius Press; 1999. p. 3-16.
12. Carlson, SE, Carver, JD, House, SC. High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: a comparison of rat neural and red cell membrane phospholipids. J Nutr 1986; 116: 718-725.
13. Piomelli, D. Arachidonic acid. Psychopharmacology: 4th Generation of Progress. Eds, Bloom, E, Kupfer, J, Part 1. New York, USA: Raven Press, (2000) http://www.acnp.org/ (accessed 13.11.08).